MyBody-X angle on MTHFR Basis

MyBody-X's angle on MTHFR is that genetic variants in this enzyme can influence homocysteine metabolism and methylation, but the clinical utility is debated. Common variants (C677T, A1298C) are associated with mildly elevated homocysteine in population studies, but the effect is modest and modulated by folate, B12, and B6 status. MyBody-X provides a risk assessment, not a diagnosis. Crucially, an MTHFR finding alone does not justify high-dose folic acid or methylfolate supplementation without medical supervision. Evidence for benefit from such supplementation in MTHFR carriers is weak, mostly mechanistic, and lacks robust clinical endpoints. Interactions with medications (e.g., methotrexate) are possible. Therefore, results should be interpreted alongside blood markers (homocysteine, folate, B12) and individual health context. MyBody-X emphasizes that the test is not a substitute for professional medical advice.